Applied Pharmacoeconomic and Outcomes Research Forum

June 8th 2009
Sixth Forum

1. AMCP Dossiers: Useful for Decision Making or Not? A Debate
2. Biologics: Drawing (or Crossing) the line of Cost vs. Benefit: A Case in Oncology
3. Quality Adjusted Life Years (QALY’s) for Decision Making: Views from Canada & the US
4. Using Large Databases to Inform Decision Making: Experience in Three Health Care Systems
5. Real World Data for Decision Making: Moving Beyond Clinical Trials
6. Pharmacoeconomics of Pharmacogenomics
Forum Objectives

Discuss commonly encountered obstacles to conducting or utilizing results of PE studies for decision making

• Explore solutions from various perspectives
  • Managed Care
  • Government
  • Pharmaceutical/Biotech Firms
  • Medical Centers
  • Academia

• Create an environment & foundation to foster larger PE/Outcomes Research Interest Group
Participants

Aetna
Aequitas
Amgen
Amylin
Bristol Meyers Squibb
E.B.D. Group
Kaiser Permanente
MedImpact Healthcare Systems
Medi-Cal Dept Health Services
Miller Pharma Consulting
Milliman
Novartis

Ortho-McNeil Janssen
Partnership for Health Analytic Research, LLC
Pfizer
Prescription Solutions
Sharp Health
Touro University
UCSD Medical Center
UCSD School of Medicine
UCSD School of Pharmacy
USC School of Pharmacy
UCSF School of Pharmacy
VA – San Diego
Steering Committee

Charles Daniels, R.Ph., Ph.D.
UCSD Healthcare Department of Pharmacy

Darlene Fujimoto, Pharm.D
Biogen-Idec (formerly)

Ted Ganiats, MD
UCSD School of Medicine

Jan D. Hirsch, R.Ph., Ph.D.
UCSD, Skaggs School of Pharmacy & Pharmaceutical Sciences

Mirta Millares, Pharm.D., FCSHP, FASHP
Kaiser Permanente – CA Regions

Anthony P. Morreale, Pharm.D., MBA, BCPS
VA San Diego Healthcare System

Robert Schoenhaus, Pharm.D.
Sharp Healthcare
Sponsors - Thanks!
Pharmacoeconomics of Pharmacogenomics
Agenda

**Moderator:** Mirta Millares, PharmD, FCSHP, FASHP  
Kaiser Permanente

| Introduction to Pharmacogenomics | Grace Kuo, PharmD, MPH  
UCSD, Skaggs School of Pharmacy & Pharmaceutical Sciences |
|----------------------------------|--------------------------------------------------|
| Genetic Technology: Practical Issues for Health Plans | Jill Van Den Bos, MA  
Milliman |

**BREAK**

| Impact of Pharmacogenomics on Drug Development & Commercialization: An International Perspective | Dave W. Miller, PhD  
Miller Pharma Consulting |
|-----------------------------------------------|--------------------------------------------------|
| Panel Q & A/Discussion  
Participant Consensus |